^
Association details:
| Biomarker: | EGFR mutation + TP53 exon 6 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
Published date:
06/27/2021
Excerpt:
Circulating tumor DNA was prospectively collected at baseline in advanced treatment-naïve EGFR-mutant lung adenocarcinoma patients treated with gefitinib in an open-label, single-arm, prospective, multicenter, phase 2 clinical trial (BENEFIT trial) and analyzed using next-generation sequencing....Mutations in TP53 exons 6 and 7 were significantly associated with inferior PFS and OS compared to wild-type TP53.
DOI:
10.1016/j.tranon.2021.101163
